Ovarian Cancer | Specialty

Novel Agents, Genetic Testing Propel Personalized Care in Ovarian Cancer

August 29th 2018

Angeles Alvarez Secord, MD, discusses recent updates in ovarian cancer, with an emphasis on the clinical significance of genetic testing.

Dr. Herzog on Novel Therapies in Ovarian Cancer

August 27th 2018

Thomas Herzog, MD, professor of obstetrics and gynecology, deputy director, University of Cincinnati Cancer Institute, discusses novel therapies in ovarian cancer.

Dr. Naumann on Neoadjuvant Chemotherapy in Patients With Ovarian Cancer

August 24th 2018

R. Wendel Naumann, MD, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses the use of neoadjuvant chemotherapy in patients with ovarian cancer.

Dr. Coleman on Immunotherapy in Ovarian Cancer

August 23rd 2018

Robert Coleman, MD, professor in the department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses ongoing research with immunotherapy in ovarian cancer.

Dr. Powell Discusses Immunotherapy in Ovarian Cancer

August 22nd 2018

Matthew Powell, MD, associate professor, Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, discusses immunotherapy in ovarian cancer.

Dr. Secord on Using Biomarkers to Guide Treatment Decisions in Ovarian Cancer

August 21st 2018

Angeles Alvarez Secord, MD, gynecologic cancers specialist, Duke Cancer Center, discusses the use of biomarkers to guide treatment decisions in patients with ovarian cancer.

Dr. Herzog on the Optimal Use of Bevacizumab in Patients With Ovarian Cancer

August 21st 2018

Thomas Herzog, MD, professor of obstetrics and gynecology, deputy director, University of Cincinnati Cancer Institute, discusses the optimal use of bevacizumab (Avastin) in patients with ovarian cancer.

Matulonis Highlights Niraparib, Immunotherapy Data in Ovarian Cancer

August 17th 2018

Ursula A. Matulonis, MD, highlights the activity and tolerability of niraparib and discusses other recent data in ovarian cancer.

Dr. Hardesty on Bevacizumab/PARP Inhibitor Combination in Ovarian Cancer

August 17th 2018

Melissa Hardesty, MD, gynecologic oncologist, Alaska Women’s Cancer Center, discusses the safety and efficacy of the bevacizumab/PARP inhibitor combination in ovarian cancer.

Patient-Experienced Toxicity Is a Biomarker Worth Considering

August 17th 2018

Maurie Markman, MD, says that the acceleration in regulatory agency approvals for novel antineoplastic agents and the focus of biomarker discovery proves that this is the era of precision medicine.

Novel Combination Shows Early Efficacy in Ovarian Cancer

August 16th 2018

David O'Malley, MD, discusses the emerging combination of mirvetuximab soravtansine plus bevacizumab and the evolving treatment landscape in ovarian cancer.

Dr. Turner on Important Steps for Genomic Profiling in Gynecologic Malignancies

August 14th 2018

Taylor Turner, MD, fellow, University of Alabama at Birmingham School of Medicine, discusses important steps to implement a genomic profiling program for gynecologic malignancies.

Dr. O'Malley on Folate-Receptor Alpha as a Biomarker in Ovarian Cancer

August 10th 2018

David O'Malley, MD, professor, Department of Obstetrics and Gynecology, The Ohio State University Comprehensive Cancer Center, discusses folate-receptor alpha as a biomarker in ovarian cancer.

Tumor Treating Fields Show Promise in Ovarian Cancer

August 7th 2018

In combination with weekly paclitaxel, tumor treating fields, an antimitotic therapy that delivers continuous low-intensity electrical fields to the tumor region, has been found safe in platinum-resistant ovarian cancer.

Dr. Konecny on Response to PARP Inhibitors in Ovarian Cancer

August 3rd 2018

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses response to PARP inhibitors in ovarian cancer.

Novel Frontline Regimens Are Emerging for Advanced Ovarian Cancer

August 2nd 2018

Bradley J. Monk, MD, and other gynecologic oncology experts from across the United States discussed how new evidence has affected their approach to treating advanced ovarian cancer.

Dr. McCann on Resistance Mutations in Ovarian Cancer

July 31st 2018

Kelly McCann, MD, PhD, a medical oncologist in the Breast Cancer Research Group at the University of California, Los Angeles, discusses resistance mutations in ovarian cancer.

Improvements in Advanced Ovarian Cancer

July 27th 2018

Novel Treatment Strategies in Recurrent Ovarian Cancer

July 27th 2018

PARP Combination Therapies in Ovarian Cancer

July 27th 2018